Pirche

PUBLISHED BY

Francisco Javier Gil-Etayo, Jairo Eduardo Niño-Ramírez, Marta Fonseca-Santos, Daniel Arroyo-Sánchez, Almudena Navarro-Bailón, Ariadna Vicente Parra, Isabel Jiménez Hernaz, Pilar Terradillos Sánchez, Francisco Boix, Miguel Alcoceba, Luis Marín, Estefanía Pérez-López, Mónica Cabrero, Ana África Martín-López, Miriam López, Mónica Baile, Alejandro Avendaño, Almudena Cabero, Ana García-Bacelar, Lourdes Vázquez, Fermín Sánchez-Guijo, Ramón García-Sanz, Lucía López-Corral, Amalia Tejeda Velarde

PUBLISHED IN

HLA

PATIENTS

145

ABSTRACT

HIGHLIGHTS

Haploidentical HSCT is a key therapy for blood cancers, but HLA disparities increase the risk of graft-versus-host disease (GvHD).

This study used the PIRCHE algorithm to quantify HLA epitope mismatches and assess their link to GvHD and clinical outcomes.

Findings showed higher PIRCHE scores correlated with earlier acute GvHD, increased chronic GvHD, and a higher relapse risk.

PIRCHE analysis may improve donor selection by predicting post-transplant outcomes in haplo-HSCT with post-transplant cyclophosphamide.

back to key milestones

2024

Stem Cell Transplant

Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy

PUBLISHED BY

PUBLISHED IN

PATIENTS

ABSTRACT

HIGHLIGHTS

Contact us